Physician profile
Hector A Robles
NPI 1548367147
$19,011.68
in general payments reported to CMS, 2019-2025
64 companies · $2,134 in 2025
The $2,134 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,643 · 2020: $2,238 · 2021: $3,696 · 2022: $2,964 · 2023: $2,352 · 2024: $1,984 · 2025: $2,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,464 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,463.51 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,291.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,879.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,421.52 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $1,393.80 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,211.86 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $988.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $802.06 | 2019-2022 | |
| Pfizer INC. | $734.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.11 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $531.22 | 2019-2025 | Leqvio |
| Sanofi-Aventis U.S. LLC | $484.45 | 2019-2025 | |
| Amarin Pharma, INC. | $396.64 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.23 | 2019-2023 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $321.30 | 2019-2022 | |
| Axsome Therapeutics, INC. | $311.46 | 2023-2024 | Sunosi |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.